Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod

Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod Novartis said the decision to terminate the sale of Sandoz US#39;s generic oral solids and dermatology businesses was taken after the companies did not get approval from the U.S. Federal Trade Commission within anticipated timelines.

No comments:

Post a Comment